SEOUL -- Cha Vaccine Institute, a vaccine specialist affiliated with South Korea's Cha Biotech, partnered with the MOGAM Institute for Biomedical Research to use artificial intelligence technology to find and develop new drug candidate materials for various vaccines.
AI is now used in various sectors to speed up research processes and reduce manpower costs. In the field of medicine and vaccines, the smart computing system will use its deep learning abilities to analyze, categorize, simulate, and test various materials to find the right candidate material.
MOGAM institute is a South Korean non-profit organization (NGO) for the development of new drugs through AI-based candidate material research. The NGO founded in 1984 as the country's first private non-profit research institute developed the world's first vaccine for orthohantavirus, also known as epidemic hemorrhagic fever.
Cha Vaccine Institute said that the company signed a memorandum of understanding with MOGAM Institute to jointly develop new drug candidate materials using AI. They will cooperate to apply for co-patents and conduct joint studies. Cha will provide test data for MOGAM's AI algorithms.
"AI is widely used to reduce time and massive costs taken in the new drug development process. We will develop new drug candidate materials for premium vaccines by combining our vaccine development capabilities and MOGAM's AI capabilities," Cha Vaccine Institute CEO Yum Jung-sun said in a statement on November 21.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.